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16S pan-bacterial PCR can
accurately identify patients
with ventilator-associated
pneumonia
Ventilator-associated pneumonia (VAP) remains
a challenge to intensive care units, with secure
diagnosis relying on microbiological cultures
that take up to 72 hours to provide a result. We
sought to derive and validate a novel, real-time
16S rRNA gene PCR for rapid exclusion of VAP.
Bronchoalveolar lavage (BAL) was obtained
from two independent cohorts of patients with
suspected VAP. Patients were recruited in a
2-centre derivation cohort and a 12-centre
conﬁrmation cohort. Conﬁrmed VAP was
deﬁned as growth of >104 colony forming
units/ml on semiquantitative culture and
compared with a 16S PCR assay. Samples were
tested from 67 patients in the derivation
cohort, 10 (15%) of whom had conﬁrmed VAP.
Using cycles to cross threshold (Ct) values as
the result of the 16S PCR test, the area under
the receiver operating characteristic (ROC) curve
(AUROC) was 0.94 (95% CI 0.86 to 1.0,
p<0.0001). Samples from 92 patients were
available from the conﬁrmation cohort, 26
(28%) of whom had conﬁrmed VAP. The
AUROC for Ct in this cohort was 0.89 (95% CI
0.83 to 0.95, p<0.0001). This study has
derived and assessed the diagnostic accuracy of
a novel application for 16S PCR. This suggests
that 16S PCR in BAL could be used as a rapid
test in suspected VAP and may allow better
stewardship of antibiotics.
Trial registration VAPRAPID trial ref
NCT01972425.
INTRODUCTION
Ventilator-associated pneumonia (VAP)
remains a signiﬁcant problem in intensive
care units (ICUs)1 and despite reductions
in reported VAP rates antibiotic use
remains high.2 The most common indica-
tion for antibiotic use remains suspected
respiratory infections.3 VAP is associated
with signiﬁcant morbidity and mortality1
especially when antibiotics are delayed or
are inadequate.4 However, due to the vari-
ous conditions that can mimic VAP, com-
monly only 30% of those suspected of
having VAP subsequently have this diagno-
sis conﬁrmed.4 The delays in obtaining
results from conventional microbiological
cultures lead to empirical use of broad-
spectrum antibiotics of which a signiﬁcant
proportion is later deemed unnecessary.
The excessive use of antibiotics is asso-
ciated with increased antimicrobial resist-
ance5 and mortality.6
The ubiquitous presence of a 16S ribo-
somal RNA gene in bacteria offers the
possibility of detecting a wide range of
bacteria in a single PCR.7 Ampliﬁcation of
the 16S rRNA gene in a PCR assay results
in ampliﬁcation of all bacteria in a
sample. Therefore, this offers potential as
a screening test for suspected VAP. The
aim of this study was to derive and
validate a real-time 16S PCR assay for
diagnosing conﬁrmed VAP.
METHODS
Samples from two previously described8 9
cohorts of adult patients with clinically
suspected VAP recruited from UK ICUs
formed the derivation8 and conﬁrmation9
cohorts respectively. Brieﬂy, patients were
recruited if they met criteria for suspected
VAP, namely new or worsening chest
X-ray changes following at least 48 hours
of ventilation, accompanied by two or
more of: temperature >38°C; white cell
count >11×109/L; or mucopurulent
sputum. In the derivation cohort patients
were excluded if they had received new
antibiotics within the 3 days prior to
recruitment;8 no such exclusion was
applied to the conﬁrmation cohort.9
Patients underwent protocolised broncho-
scopic bronchoalveolar lavage (BAL)8 9
and an aliquot of BAL ﬂuid was processed
using a semiquantitative culture method.
This culture was used as our reference
diagnostic standard, with growth at >104
colony forming units/mL (CFU/mL) of
BAL ﬂuid being deﬁned as ‘VAP positive’
and growth <104 CFU/mL as ‘VAP nega-
tive’, these cut-offs being in line with
established standards.1 4
Full details of sample processing are
described in the online supplementary
section. Brieﬂy, the fraction of lavage not
used for conventional culture was centri-
fuged to produce a cell-free supernatant,
followed by nucleic acid extraction. The
16S PCR assays are described below; assay
1 and assay 2 were conducted in geo-
graphically separate laboratories.
Real-time 16S PCR assay 1
The primer and probe sequences targeting
the16S rRNA gene have been described
previously.10 The probe contained a car-
boxyﬂuorescein (FAM) label on the 50 end
with a Black Hole Quencher 1 (BHQ1)
on the 30 end. Primers and probe were
synthesised by Eurogentec (Liège,
Belgium). The ﬁnal 16S PCR reaction mix
contained 1.25U HotStarTaq polymerase
and 1× reaction buffer (Qiagen,
Manchester, UK), 4 mM MgCl2, 0.2 mM
deoxynucleotide mix (dNTP), 0.25 mM
primer 27-F, 0.75 mM primer 16S 1RR-B,
0.3 mM probe 514-S, nuclease-free water
(Promega, Southampton, UK) and 10 mL
nucleic acid extract to a ﬁnal volume of
25 mL. Real-time PCR was carried out on
the ABI 7500 instrument (Applied
Biosystems, Life Technologies, Paisley, UK).
This assay was used for samples from the
derivation cohort, to establish proof in
principle of the diagnostic utility of this
approach, and was also used for samples
from the conﬁrmation cohort.
Real-time 16S PCR assay 2
The primer and hybridisation probe
sequences targeting the 16S rRNA gene
have been described previously.11 The
hybridisation probe contained a FAM
label on the 50 end with a BHQ1 on the
30 end. Primers and hybridisation probe
were synthesised by Sigma Genosys
(Sigma-Aldrich, Ebersberg, Germany).
The ﬁnal 16S PCR reaction mix con-
tained 1X Platinum uracil DNA glycosy-
lase Mastermix (Life Technologies, Paisley,
UK), 0.2 mM bovine serum albumin
(Sigma, Dorset, UK), a total of 4 mmol/L
MgCl2, 0.4 mM forward and reverse
primers, 0.1 mM hybridisation probe,
nuclease-free water (Promega,
Southampton, UK) and 2 mL of target
template for a ﬁnal reaction volume of
10 mL. Real-time qPCR was carried out
on a Light Cycler 480 instrument (Roche,
Indianapolis, Indiana, USA). This assay
was used on samples from the conﬁrm-
ation cohort only.
For the purposes of analysis, the metric
was cycles to cross threshold (Ct) as a
measure of 16 s rRNA gene load and
hence bacterial burden. A higher bacterial
load will result in a lower time to cross
threshold, that is, a lower Ct value.
Details of statistical analyses used can be
found in the online supplementary
methods section. Both studies had
approvals from relevant research ethics
committees; full details are in the online
supplementary section.
RESULTS
In the derivation cohort, samples from 67
patients were available, of whom 10 (15%)
had ‘microbiologically conﬁrmed VAP’. In
the ‘conﬁrmation’ cohort samples from 92
patients were available for analysis; 26
(28%) met the culture criteria for ‘microbio-
logically conﬁrmed VAP’. The demographic
details and organisms cultured are shown in
the online supplementary section (see
online supplementary tables S1 and S2).
16S PCR assay 1 demonstrated that
patients with conﬁrmed VAP had a higher
bacterial burden, as signiﬁed by a lower Ct
value, than those without VAP (ﬁgure 1A).
When evaluated for diagnostic ability by
ROC curve, assay 1 demonstrated excellent
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diagnostic ability (see table 1 and ﬁgure
S1A) with an area under the ROC curve
(AUROC) of 0.94 (95% CI 0.86 to 1.00),
sensitivity of 100% and speciﬁcity 72% at
the most optimal cut-off.
In the conﬁrmation cohort, patients
with conﬁrmed VAP had signiﬁcantly
lower 16S Ct values (ﬁgure 1B), and a
similar diagnostic performance was
demonstrated (table 1 and ﬁgure S1B),
with sensitivity of 100% and speciﬁcity of
67% at the most optimal cut-off. The
difference between the AUROC of the
cohorts was not statistically signiﬁcant
(p=0.56).
Samples from the conﬁrmation cohort
were also tested using 16S assay 2. As
seen in ﬁgure 1C, although the absolute
Ct values differed between the two assays,
the same relationship between VAP and
non-VAP samples was observed. ROC ana-
lysis (table 1 and ﬁgure S1C) demon-
strated good diagnostic ability (area under
the curve 0.84 95% CI 0.75 to 0.94) with
sensitivity 89% and speciﬁcity 80% at the
optimal cut-off. Although the point esti-
mates of AUROC were higher for assay 1,
the difference did not achieve statistical
signiﬁcance (p=0.4). However if the
assays are compared at maximal sensitivity
(100%), the speciﬁcity of assay 1 is signiﬁ-
cantly higher (table 1). Using the Youden
Index to deﬁne optimal Ct value cut-offs
on the ROC curve, a ‘positive’ result for
16S would be a value below this cut-off
(indicating high bacterial load) and a
‘negative’ result would be a value above
this cut-off (indicating low bacterial load).
In the derivation cohort, 35 (52%)
patients were receiving antibiotics on the
day of recruitment. In the conﬁrmation
cohort, 69 (75%) were receiving antibio-
tics and 14 (15%) had undergone a
change of antibiotics within the past
3 days. Receipt of antibiotics and recent
change in antibiotics were not associated
with changes in 16S Ct values (see online
supplementary results and table S3).
Figure S2 shows the relationship
between Ct values for the two 16S assays,
demonstrating a non-linear association.
DISCUSSION
To our knowledge, this is the ﬁrst report
of the use of real-time 16S PCR for diag-
nosing VAP. Although 16S rRNA gene
sequencing has been used to explore the
microbiome of ventilated patients, data on
its diagnostic potential have been absent.
In deriving and conﬁrming a test, with a
high agreement in test performance
between the two cohorts, we demonstrate
clear potential for the clinical utility of
this test. Turnaround time is 4–6 hours;
therefore, this test could impact on anti-
biotic use, which may otherwise only be
rationalised following the results of con-
ventional cultures at 48–72 hours.
This study has a number of strengths.
First, we were able to perform derivation
and conﬁrmation in two distinct cohorts,
with conﬁrmation in a cohort recruited from
a diverse group of 12 ICUs. The results are
therefore likely to be widely applicable;
Figure 1 Real-time 16S PCR results as
expressed by cycles to cross threshold
(Ct) for samples from patients. (A) Ct
values from assay 1 among derivation
cohort patients with and without
conﬁrmed ventilator-associated
pneumonia (VAP). N=67, 57 non-VAP
and 10 VAP, error bars show median
and IQR. **** p<0.0001 by
Mann-Whitney U test. (B) Ct values from
assay 1 among conﬁrmation cohort
patients with and without conﬁrmed
VAP. N=92, 66 non-VAP and 26 VAP,
error bars show median and IQR. ****
p<0.0001 by Mann-Whitney U test. (C)
Ct values from assay 2 among
conﬁrmation cohort patients with and
without conﬁrmed VAP. N=92, 66
non-VAP and 26 VAP, error bars show
median and IQR. **** p<0.0001 by
Mann-Whitney U test.
Table 1 Diagnostic performance of the two 16S assays
Curve Assay 1 derivation
Assay 1
confirmation
Assay 2
confirmation
AUC ROC 0.94 (0.86 to 1.0)
p<0.0001
0.89 (0.83 to 0.95)
p<0.0001
0.84 (0.75 to 0.94)
p<0.0001
Youden optimum cut-off (Ct) 29.85 29.43 21.59
Youden optimum sensitivity/specificity
(95% CIs)
100 (69 to 100)/72
(58 to 83)
100 (87 to 99)/67
(54 to 78)
89 (70 to 98)/80
(69 to 89)
Maximum sensitivity optimum cut-off (Ct) 29.85 29.43 22.02
Maximum sensitivity/specificity (95% CIs) 100 (69 to 100)/72
(58 to 83)
100 (87 to 100)/67
(54 to 78)
100 (86 to 100)/15
(8 to 26)
(ROC curves displayed in online supplementary figure S1).
As avoiding false-negative results is important in rapid tests for VAP, we also report the specificity at maximum (100%)
sensitivity.
AUC, area under the curve; Ct, cycles to crossing threshold; VAP, ventilator-associated pneumonia.
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indeed, the microbiological spectrum found
is similar to reports from other countries.4
Second, by using consistent diagnostic proce-
dures within each cohort, we avoided some
of the problems which occur with the diag-
nosis of VAP.1 4 Our rate of microbiologically
conﬁrmed VAP in both cohorts (23%) is at
the lower end of the reported range4 but not
out of keeping with other reports and we
believe this may, in part, reﬂect the use of
highly standardised BAL protocols.
A disadvantage of this study is that
samples were obtained bronchoscopically,
requiring resource and exposing patients
to a small but deﬁnite risk, and the applic-
ability of this test to other sample types
cannot be inferred. The assays we describe
here are also limited to bacterial detection.
The differences between the two assays
tested, and the use of stored samples, high-
light the need for external prospective valid-
ation before this measure could be
implemented in routine clinical practice.
Further reﬁnements of assays may also
improve diagnostic performance. The refer-
ence standard of growth of organisms on
conventional culture, remains imperfect, and
indeed may well be inﬂuenced by intercur-
rent antibiotics generally, and recent changes
in antibiotics speciﬁcally.12 However this
remains the established standard4 and is used
routinely for clinical decision-making. As
such, the 16S assay described here can
predict the results of a clinically relevant test,
but within 6 hours rather than the 48–
72 hours taken for the conventional cultures.
In conclusion, we have derived and
conﬁrmed the diagnostic utility of a rapid
laboratory test for VAP in a multicentre
setting. We propose that this test has the
potential to permit rapid decisions to
direct antimicrobial therapy in patients
with suspected VAP thus improving stew-
ardship of antibiotics in the ICU.
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